Foundation Shares CF Expertise to Inform ICER Assessment

The Institute for Clinical and Economic Review (ICER) developed an assessment of the comparative clinical effectiveness and value of cystic fibrosis therapies. The Foundation provided input to help inform this process.

May 9, 2018 | 2 min read

The Institute for Clinical and Economic Review (ICER) is an independent nonprofit research institute that analyzes the value of medications at their current cost. ICER's assessment of cystic fibrosis therapies included ivacaftor (Kalydeco®), lumacaftor/ivacaftor (Orkambi®), and tezacaftor/ivacaftor (Symdeko®).

Overall, policymakers and public and private insurance companies are looking for more information to help them make informed coverage decisions and to better understand the value of therapies. ICER is one entity that has stepped in to try to fill this gap.

Throughout the development of their evaluation, ICER invited public comment to help inform and shape their assessment. The final report was published on May 3, 2018. It will be the subject of a public meeting hosted by ICER on May 17, 2018.

During the meeting, an independent panel will discuss and vote on the comparative clinical effectiveness, benefits or disadvantages, and other contextual considerations of the therapies. The implications of the vote will also be discussed among a roundtable of clinical experts and patients. On behalf of the Foundation, Mary Dwight, senior vice president of policy and advocacy, and Dr. Michael Boyle, senior vice president of therapeutics development, will be attending and presenting.  

See below for a list of our submitted, public comments:

Share this article
Our Advocacy Work
Recent news
Cystic Fibrosis Community Perspectives Influence Future of CF Care Model
News | 4 min read
CF Foundation Adapts Registry Reporting to New Race-Neutral Standards
News | 5 min read
Nearly 350 Advocates Urge Congressional Action During 17th Annual March on the Hill
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.